Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 13 of 13 publications.

Doane MJ, Boeri M, Vass C, Bussberg C, Panchmatia HR, Citrome L, Sajatovic M. Preferences for attributes of oral antipsychotic treatments: results from a discrete-choice experiment in respondents with schizophrenia or bipolar I disorder. BMC Psychiatry. 2024 Sep 10;24(1):605. doi: 10.1186/s12888-024-06034-

Ravelo A, Myers K, Brumble R, Bussberg C, Koffman B, Manzoor BS, Biondo JML, Mansfield C. Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment. Future Oncol. 2024;20(28):2059-70. doi: 10.1080/14796694.2024.2348440

Li D, Tan A, Hernandez S, Reilly N, Bussberg CJ, Mansfield C. Patient preferences for unresectable hepatocellular carcinoma (HCC) treatments. Poster presented at the 20th Annual International Society of Gastrointestinal Oncology; October 13, 2023. Tempe, AZ. Previously presented at the ESMO 24th World Congress on Gastrointestinal Cancer 2022.

Doane MJ, Boeri M, Vass C, Bussberg C, Panchmatia HR, Gasper S, Citrome L, Sajatovic M. Preferences for characteristics of oral antipsychotic treatments: survey results of patients living with bipolar I disorder. Poster presented at the 2023 ISBD Annual Conference; June 22, 2023. Chicago, IL.

Poulos C, Mansfield C, Bussberg CJ, Hicks JC, Downey C. Advancing equity, diversity, inclusion, and belonging in patient centered drug development with patient preference research. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S359. doi: 10.1016/j.jval.2023.03.2791

Doane MJ, Boeri M, Vass CM, Bussberg CJ, Panchmatia HR, Gasper S, Citrome L, Sajatovic M. Preferences for characteristics of oral antipsychotic treatments: survey results of patients living with schizophrenia. Poster presented at the SIRS 2023 Congress; May 13, 2023. Toronto, Canada.

Bhattacharya R, Vass C, Pinto CA, Myers K, Imai K, Bussberg C, Calhoun SR, Poulos C. Exploring perceptions of the risk of recurrence in renal cell carcinoma: evidence from a survey of practicing physicians. Poster presented at the 2023 American Urological Association Annual Meeting; April 28, 2023. Chicago, IL. [abstract] J Urol. 2023 Apr 1; 209(Supplement 4):e271. doi: 10.1097/JU.0000000000003244.15

Li D, Tan R, Hernandez S, Reilly N, Bussberg C, Mansfield C. Patient preferences for unresectable hepatocellular carcinoma treatments: a discrete-choice experiment. Cancers. 2023 Feb 25;15(5):1470. doi: 10.3390/cancers15051470

Vass C, Pinto CA, Myers K, Imai K, Bussberg C, Bhattacharya R, Calhoun SR, Poulos C. Heterogeneity in physician and patient preferences for the treatment of renal cell carcinoma: evidence from latent class analysis. Poster presented at the 2023 ASCO Genitourinary Cancers Symposium; February 16, 2023. San Franciso, CA. [abstract] J Clin Oncol. 2023 Feb 20; 41(Suppl 6):661. doi: 10.1200/JCO.2023.41.6_suppl.661

Calhoun SR, Vass C, Myers K, Imai K, Bussberg C, Bhattacharya R, Pinto CA, Poulos C. Patient and physician preferences for adjuvant treatment of renal cell carcinoma: a discrete-choice experiment. Poster presented at the 2023 ASCO Genitourinary Cancers Symposium; February 16, 2023. San Franciso, CA. [abstract] J Clin Oncol. 2023 Feb 20; 41(Suppl 6):635. doi: 10.1200/JCO.2023.41.6_suppl.635

Ravelo A, Myers K, Brumble R, Bussberg C, Koffman B, Manzoor BS, Biondo J, Mansfield C. Understanding patient preferences for chronic lymphocytic leukemia treatments. Poster presented at the 64th ASH Annual Meeting and Exposition; December 12, 2022. New Orleans, LA.

Li D, Tan A, Hernandez S, Reilly N, Bussberg C, Mansfield C. Predicting treatment choices for unresectable hepatocellular carcinoma (HCC): results from a patient preference study. Poster presented at the AASLD 2022 The Liver Meeting; November 4, 2022. Washington, DC. [abstract] Hepatology. 2022 Oct 21; 76(S1):S1312. doi: 10.1002/hep.32697

Li D, Tan A, Hernandez S, Reilly N, Bussberg CJ, Mansfield C. Patient preferences for unresectable hepatocellular carcinoma (HCC) treatments: balancing overall survival and quality of life. Poster presented at the ESMO 24th World Congress on Gastrointestinal Cancer 2022; June 2022. Barcelona, Spain. [abstract] Ann Oncol. 2022 Jun; 33(Suppl 4):s293.